Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
Mirabegron
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:ATCCode |
G04BD12
|
| gptkbp:brand |
gptkb:Myrbetriq
|
| gptkbp:CASNumber |
223673-61-8
|
| gptkbp:developedBy |
gptkb:Astellas_Pharma
|
| gptkbp:hasMolecularFormula |
C21H24N4O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
YM-178
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
beta-3 adrenergic receptor agonist
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
hypertension urinary tract infection |
| gptkbp:usedFor |
overactive bladder
|
| gptkbp:bfsParent |
gptkb:mirabegron
|
| gptkbp:bfsLayer |
7
|